# Irinotecan-Eluting Bead (DEBIRI) for Patients With Liver Metastases From Colorectal Cancer

> **NCT03175016** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Colon Cancer Liver Metastasis

## Interventions

- **PROCEDURE:** TACE
- **DRUG:** Irinotecan
- **DEVICE:** eluting-bead

## Key facts

- **NCT ID:** NCT03175016
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-06-20
- **Primary completion:** 2019-08
- **Final completion:** 2019-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2017-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03175016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03175016, "Irinotecan-Eluting Bead (DEBIRI) for Patients With Liver Metastases From Colorectal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03175016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*